期刊文献+

西格列汀联合甘精胰岛素治疗2型糖尿病疗效观察 被引量:1

暂未订购
导出
摘要 目的:探讨西格列汀联合甘精胰岛素治疗糖尿病的效果。方法:收治糖尿病患者58例,将入组的所有患者采用随机的方式进行分组,一组为观察组共30例患者,本组服用西格列汀联合甘精胰岛素进行治疗;一组为对照组共28例患者,本组服用阿卡波糖联合甘精胰岛素进行治疗。将两组疗效进行比较,观察两组治疗后FBG、2hPG、HbA1C、低血糖发生率。结果:两组治疗后,FBG、2hPG、HbA1C指标均较前下降(P<0.01)。且观察组低血糖发生率低于对照组(P<0.05)。结论:西格列汀联合甘精胰岛素能有效控制血糖,低血糖发生率低,具有安全方便的特点。 Abstract Objective:We investigate the therapeutic effect of sitagliptin combomed with insulin glargine in treatment of diabetes mellitus.Methods':We have treated 58 cases of diabetic patients between 2010 November to 2013 March,these patients were randomly divided into two groups. The observation group itleiuded 30 patients and these pa-tients were treated by sitagliptin combined with insulin glargine.The control group in-cluded 28 patients and these patients were treated by Acarbose combined with in,ulin glargine.Finally,results of treatment of two groups such as FBG,2hPG,HbAic,incidence of hypoglycemia were compared.Results:Af-ter tteafment,FBG,2hPG,HbAic index of the two groups were decreased (P〈0.01).The incidence of hypoglycemia of observation group was lower than the control group(P 〈 0.05).Conelusion: Sitagliptin combined with insulin glargine can effectively control blood glueose with Low rates of hypoglycemia and of is safe and convenient.
出处 《中国社区医师(医学专业)》 2013年第24期21-22,共2页
关键词 西格列汀 甘精胰岛素 阿卡波糖 2型糖尿病 Sitagtiptin insulin glargine Acarbose Type 2 diabetes mellitus
  • 相关文献

参考文献9

二级参考文献29

  • 1陈超,莫尉林,邢学农,李素梅,叶山东,任安.甘精胰岛素、NPH胰岛素联合口服降糖药在2型糖尿病患者中的应用[J].安徽医学,2006,27(4):262-264. 被引量:4
  • 2刘新艮.实用内分泌学[M].第3版.北京:人民军医出版社,2004.1182.
  • 3Fiona TH Lee. Advances in diabetes therapy in the elderly[J]. J Pharrn Pract Res, 2009, 39(1): 63-67.
  • 4Barzilai N, Guo H, Mahoney EM, et al. Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial[J]. Curr Med Res Opin, 2011, 27(5): 1049-1058.
  • 5Mohan V, Yang W, Son HY, et al. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea[J]. Diabetes Res Clin Pract, 2009, 83(1): 106-116.
  • 6Amori R, Lau J, Pitt,as A. Efficacy and safety of incretin therapy in type 2 diabetes[J]. JAMA, 2007, 298: 194-206.
  • 7Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic {beta}- cell mass and function in a rodent model of type 2 diabetes[J]. Diabetes, 2006, 55(6): 1695-1704.
  • 8Scheen AJ. Pharmacokinetics of dipeptidyl peptidase-4 inhibitors[J]. Diabetes Obes Metab, 2010, 12(8): 648-658.
  • 9Xu L, Man CD, Charbonnel B, et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell fimction in patients with type 2 diabetes: a model-based approach[J]. Diabetes Obes Metab, 2008, 10(12): 1212-1220.
  • 10Schwartz SL. Treatment of elderly patients with type 2 diabetes mellitus: a systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors[J]. Am J Geriatr Pharmacother, 2010, 8(5): 405-418.

共引文献101

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部